T. Rowe Price Associates
BMY icon

T. Rowe Price Associates’s Bristol-Myers Squibb BMY Stock Holding History

T. Rowe Price Associates’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,560,000
Closed -$150M – 2572
2016
Q4 		$150M Buy
+2,560,000
New +$140M 0.03% 483

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates's BMY Position: Q1 2026 in Review

T. Rowe Price Associates increased its Bristol-Myers Squibb (BMY) stake by 49% in Q1 2026, buying an estimated $196M and bringing the position to 10,250,238 shares worth $622M. The position accounts for 0.07% of the portfolio, ranked #219.

T. Rowe Price Associates first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.31B in Q2 2016. 2,528 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • T. Rowe Price Associates held 10,250,238 shares of Bristol-Myers Squibb worth $622M as of Q1 2026.
  • T. Rowe Price Associates bought 3,370,763 Bristol-Myers Squibb shares in Q1 2026, an estimated $196M.
  • Bristol-Myers Squibb made up 0.07% of T. Rowe Price Associates's portfolio in Q1 2026, its #219 holding.
  • T. Rowe Price Associates first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's Bristol-Myers Squibb position peaked at $5.31B in Q2 2016.
  • 2,528 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.